It reduces the absorbed dose ranging from 9 to 53%
That is beyond the capacity of a standard insulin syringe and would require either two separate injections or a different syringe type entirely
That injury triggers cellular turnover: the damaged skin sheds and new, healthier cells rise to replace it
Additionally, tirzepatide carries FDA warnings about pancreatitis, gallbladder disease, acute kidney injury risk with dehydration, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
It also supports weight loss and obesity management in individuals with weight-related health conditions
This may have been the main impetus of Novos decision not to make the payment and allow the particular patent to lapse, likely not an oversight. In this view, letting the patent lapse might have simply been a low-cost calculation, especially if Novo believed their core IP protection was set to expire soon